
Quarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Net Debt 2011-2026 | RNLX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Renalytix AI plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 24.5 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.5 K | 24.5 K | 24.5 K |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 113.78 | 2.96 % | $ 34.6 B | ||
|
Celcuity
CELC
|
-28.1 M | $ 140.34 | 7.16 % | $ 6.56 B | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 2.39 | 21.32 % | $ 3.18 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
-106 M | $ 20.03 | 4.32 % | $ 581 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.41 | 2.88 % | $ 496 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
1.15 B | $ 114.97 | 17.09 % | $ 14.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 21.15 | 3.02 % | $ 1.13 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 115.09 | 1.36 % | $ 9.49 B | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.8 | - | $ 7.96 M | ||
|
Illumina
ILMN
|
-494 M | $ 141.92 | 0.17 % | $ 22.6 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 96.09 | 3.44 % | $ 6.49 B | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 421.87 | 0.47 % | $ 12.2 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 156.03 | 2.36 % | $ 7.73 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 082.67 | 3.05 % | $ 22.3 B | ||
|
NeoGenomics
NEO
|
187 M | $ 8.9 | 6.08 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 19.26 | 2.72 % | $ 431 M | ||
|
Natera
NTRA
|
-177 M | $ 204.92 | 4.53 % | $ 20.2 B | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
-22.8 M | $ 3.81 | 7.32 % | $ 353 M | ||
|
Personalis
PSNL
|
-117 M | $ 7.95 | 12.93 % | $ 709 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 26.74 | 2.67 % | $ 25.4 B | ||
|
Senseonics Holdings
SENS
|
-4.15 M | $ 5.71 | 3.07 % | $ 238 M | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
-19.5 M | - | - | $ 2.69 B | ||
|
Thermo Fisher Scientific
TMO
|
29.6 B | $ 451.79 | 0.9 % | $ 170 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.35 | -1.26 % | $ 5.4 M | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.6 | 6.95 % | $ 216 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 257.42 | 1.49 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | $ 53.66 | 8.4 % | $ 3.21 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
751 M | $ 8.83 | 5.75 % | $ 1.92 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 193.75 | 1.92 % | $ 21.5 B | ||
|
Waters Corporation
WAT
|
391 M | $ 341.32 | 2.37 % | $ 20.3 B |